| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
MALT1 protease[1][2][3]
|
|---|---|
| ln Vitro |
In both mouse and rat tumors, safimaltib (JNJ-67856633) is efficient and highly bioavailable, sometimes resulting in tumor stasis. According to serum IL10 levels or uncleaved BCL10 levels in tumors, safimaltib produced a strong in vivo pharmacodynamic shutdown in both CD79b- and CARD11-mutant ABC-models of DLBCL [1][3].
|
| ln Vivo |
JNJ-67856633 administration was associated with a dose-dependent decrease of Tregs (CD4+CD25+FoxP3+) generation following CD3/28 activation, which shows that MALT1 inhibition may have an immunomodulatory effect [3].
|
| References | |
| Additional Infomation |
Safilmatinib is an orally bioavailable inhibitor of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) with potential antitumor activity. After administration, safilmatinib targets and binds to MALT1, inhibiting its activity. This inhibits the MALT1-dependent signaling pathway, reduces interleukin-10 (IL-10) levels, and upregulates interferon (IFN) levels. Ultimately, this leads to inhibition of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) and nuclear factor-κB (NF-κB) signaling pathways, inducing apoptosis and inhibiting the growth of MALT1-expressing tumor cells. MALT1 belongs to the caspase family and is the active component of the CARD11-BCL10-MALT1 (CBM) signaling complex. It plays an important role in B cell and T cell activation and is overactivated in some tumor cells.
|
| Molecular Formula |
C20H11F6N5O2
|
|---|---|
| Molecular Weight |
467.324064493179
|
| Exact Mass |
467.081
|
| CAS # |
2230273-76-2
|
| PubChem CID |
134609793
|
| Appearance |
Off-white to yellow solid powder
|
| LogP |
2.9
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
33
|
| Complexity |
788
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
FC(C1=C(C(NC2C=CN=C(C(F)(F)F)C=2)=O)C=NN1C1=CC=CC2C(NC=CC1=2)=O)(F)F
|
| InChi Key |
APWRZPQBPCAXFP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H11F6N5O2/c21-19(22,23)15-8-10(4-6-27-15)30-18(33)13-9-29-31(16(13)20(24,25)26)14-3-1-2-12-11(14)5-7-28-17(12)32/h1-9H,(H,28,32)(H,27,30,33)
|
| Chemical Name |
1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 125 mg/mL (267.48 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.45 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.45 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.45 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1399 mL | 10.6993 mL | 21.3986 mL | |
| 5 mM | 0.4280 mL | 2.1399 mL | 4.2797 mL | |
| 10 mM | 0.2140 mL | 1.0699 mL | 2.1399 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
